Genmab A/S (0MGB) Share Forecast & Price Target

Compare

14 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0MGB Analyst Ratings

Moderate Buy

5 Buy

2 Hold

1 Sell

Based on 8 analysts giving stock ratings to

Genmab

A/S

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0MGB Stock 12 Month Forecast

Average Price Target

kr2,258.88

▲(36.47% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is kr2,258.88 with a high forecast of kr2,750.00 and a low forecast of kr1,400.00. The average price target represents a 36.47% change from the last price of kr1,655.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1295":"kr1,295","1659":"kr1,659","2023":"kr2,023","2387":"kr2,387","2751":"kr2,751"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2258.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr2.26K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.40K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1295,1659,2023,2387,2751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1866.181,1934.167076923077,2002.1531538461538,2070.139230769231,2138.1253076923076,2206.111384615385,2274.0974615384616,2342.0835384615384,2410.0696153846156,2478.0556923076924,2546.041769230769,2614.0278461538464,2682.013923076923,{"y":2750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1866.181,1896.3886153846154,1926.5962307692307,1956.8038461538463,1987.0114615384616,2017.219076923077,2047.4266923076923,2077.6343076923076,2107.841923076923,2138.0495384615388,2168.257153846154,2198.4647692307694,2228.6723846153845,{"y":2258.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1866.181,1830.320923076923,1794.4608461538462,1758.6007692307692,1722.7406923076924,1686.8806153846153,1651.0205384615385,1615.1604615384615,1579.3003846153847,1543.4403076923077,1507.5802307692309,1471.7201538461538,1435.860076923077,{"y":1400,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1422.886,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1608.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1296.749,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1401.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1420.738,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1387.143,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1624.886,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1965.403,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1857.698,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2073.006,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2028.488,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2089.284,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.181,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr2,750

Average Price Targetkr2,259

Lowest Price Targetkr1,400

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

kr2,500

Buy

51.04%

Upside

Reiterated

03/13/26

Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)

Justin Smith

Bernstein

kr1,015→kr1,400

Sell

-15.42%

Downside

Reiterated

02/23/26

Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks

Rajan Sharma

Goldman Sachs

kr1,793→kr1,771

Hold

7.00%

Upside

Reiterated

02/18/26

Goldman Sachs Keeps Their Hold Rating on Genmab A/S (0MGB)

Charlie Haywood

Bank of America Securities

kr2,500

Buy

51.04%

Upside

Reiterated

02/18/26

Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside

Benjamin Jackson CFA

Jefferies

kr2,650

Buy

60.10%

Upside

Initiated

02/16/26

Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target

Xian Deng

UBS

kr2,750

Buy

66.15%

Upside

Reiterated

01/19/26

Genmab A/S (0MGB) Gets a Buy from UBS

Jon Berggren

Kepler Capital

kr2,100

Hold

26.87%

Upside

Reiterated

01/19/26

Kepler Capital Sticks to Its Hold Rating for Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

kr2,000→kr2,400

Buy

45.00%

Upside

Reiterated

01/06/26

Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche BankGenmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank

Zain Ebrahim

J.P. Morgan

kr1,650→kr2,050

Hold

23.85%

Upside

Reiterated

12/08/25

Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

kr2,300→kr2,000

Buy

20.83%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Michael Novod CFA

Nordea Markets

Not Ranked

Nordea Markets

kr2,009

Buy

21.38%

Upside

Upgraded

05/09/25

Genmab upgraded to Buy from Hold at NordeaGenmab upgraded to Buy from Hold at Nordea

Rajesh Kumar

HSBC

kr2,970→kr1,990

Buy

20.23%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

kr1,400→kr1,300

Hold

-21.46%

Downside

Reiterated

04/16/25

Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,300 at BNP Paribas ExaneBNP Paribas Exane analyst Victor Floch lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK1,300.00 (from DKK1,400.00) while maintaining a Neutral rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

kr2,500

Buy

51.04%

Upside

Reiterated

03/13/26

Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)

Justin Smith

Bernstein

kr1,015→kr1,400

Sell

-15.42%

Downside

Reiterated

02/23/26

Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks

Rajan Sharma

Goldman Sachs

kr1,793→kr1,771

Hold

7.00%

Upside

Reiterated

02/18/26

Goldman Sachs Keeps Their Hold Rating on Genmab A/S (0MGB)

Charlie Haywood

Bank of America Securities

kr2,500

Buy

51.04%

Upside

Reiterated

02/18/26

Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside

Benjamin Jackson CFA

Jefferies

kr2,650

Buy

60.10%

Upside

Initiated

02/16/26

Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target

Xian Deng

UBS

kr2,750

Buy

66.15%

Upside

Reiterated

01/19/26

Genmab A/S (0MGB) Gets a Buy from UBS

Jon Berggren

Kepler Capital

kr2,100

Hold

26.87%

Upside

Reiterated

01/19/26

Kepler Capital Sticks to Its Hold Rating for Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

kr2,000→kr2,400

Buy

45.00%

Upside

Reiterated

01/06/26

Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche BankGenmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank

Zain Ebrahim

J.P. Morgan

kr1,650→kr2,050

Hold

23.85%

Upside

Reiterated

12/08/25

Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

kr2,300→kr2,000

Buy

20.83%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Michael Novod CFA

Nordea Markets

Not Ranked

Nordea Markets

kr2,009

Buy

21.38%

Upside

Upgraded

05/09/25

Genmab upgraded to Buy from Hold at NordeaGenmab upgraded to Buy from Hold at Nordea

Rajesh Kumar

HSBC

kr2,970→kr1,990

Buy

20.23%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

kr1,400→kr1,300

Hold

-21.46%

Downside

Reiterated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab A/S

3 Months

xxx

Success Rate

10/20 ratings generated profit

Average Return

+4.04%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +4.04% per trade.

1 Year

Emmanuel PapadakisDeutsche Bank

Success Rate

12/20 ratings generated profit

Average Return

+7.51%

reiterated a buy rating 3 months ago

Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +7.51% per trade.

2 Years

xxx

Success Rate

14/20 ratings generated profit

Average Return

+11.11%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +11.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MGB Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0MGB has received 11 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. 0MGB average Analyst price target in the past 3 months is 2,258.88.

Each month's total comprises the sum of three months' worth of ratings.

0MGB Financial Forecast

0MGB Earnings Forecast

Next quarter’s earnings estimate for 0MGB is kr10.13 with a range of kr2.63 to kr17.20. The previous quarter’s EPS was kr3.21. 0MGB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.

0MGB Sales Forecast

Next quarter’s sales forecast for 0MGB is kr5.92B with a range of kr5.30B to kr6.76B. The previous quarter’s sales results were kr6.79B. 0MGB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.

0MGB Stock Forecast FAQ

What is GB:0MGB’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is 2,258.88.

What is GB:0MGB’s upside potential, based on the analysts’ average price target?

Genmab A/S has 36.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genmab A/S a Buy, Sell or Hold?

Genmab A/S has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.

What is Genmab A/S’s share price target?

The average share price target for Genmab A/S is 2,258.88. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,750.00 ,and the lowest forecast is kr1,400.00. The average share price target represents 36.47% Increase from the current price of kr1,655.18.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Genmab A/S?

To buy shares of GB:0MGB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Genmab A/S (0MGB) Share Forecast & Price Target

0MGB Analyst Ratings

0MGB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab A/S

0MGB Analyst Recommendation Trends

0MGB Financial Forecast

0MGB Earnings Forecast

0MGB Sales Forecast

0MGB Stock Forecast FAQ

Detailed List of Analyst Forecasts